AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- PME delivers strong revenue and profit growth with cutting-edge radiology tech
- JHX remains resilient with durable building materials and global footprint
- PME and JHX demonstrate healthy return on equity, signaling business efficiency
Two standout names on the ASX in 2025 — Pro Medicus (ASX:PME) and James Hardie Industries (ASX:JHX) — are capturing interest for distinct reasons. One operates in healthcare technology, and the other in building materials, but both exhibit financial strength and innovation in their respective fields.
Pro Medicus (ASX:PME)
Pro Medicus has been making waves in the medical technology space with its radiology IT software solutions. Founded in 1983, the company has developed an advanced suite of products that includes Radiology Information Systems (RIS), Picture Archiving and Communication Systems (PACS), and visualization tools. These products cater to hospitals and imaging centers worldwide.
A major differentiator for Pro Medicus is its Visage software platform, which empowers radiologists to review large medical images remotely — even on mobile devices. This technology provides a faster, more flexible approach to diagnosis, which can contribute to better healthcare outcomes by enhancing decision-making speed and accuracy.
Financially, the company continues to exhibit strong growth characteristics. Since FY21, revenue has increased by 33.4% annually, reaching $162 million in FY24. During the same period, net profit surged from $31 million to $83 million. A robust return on equity of 50.7% underscores efficient capital deployment and high business profitability.
James Hardie Industries (ASX:JHX)
James Hardie Industries is a global leader in fiber cement and gypsum-based building products, with a presence across North America, Europe, Australia, and New Zealand. Employing over 5,200 people, the company is known for materials that offer durability, water and termite resistance, and low maintenance requirements — factors that appeal strongly to both residential and commercial builders.
Despite challenges in the construction sector, James Hardie’s long-term fundamentals remain solid. Over the past three fiscal years, the company has grown revenue by 10.6% annually, culminating in $3.94 billion in FY24. Net profit more than doubled from $263 million to $510 million. The return on equity stands at 29.4%, reflecting healthy profitability and effective management.
Both Pro Medicus and James Hardie Industries are showing signs of operational excellence through innovation, global presence, and consistent financial growth. Their respective industries may be quite different, but strong revenue expansion, rising profitability, and efficient use of shareholder capital mark them as companies to keep an eye on as the year progresses.
